Westinghouse to Supply OKG with Nuclear Fuel until 2030
Westinghouse Electric Company today announced that it has signed a nuclear fuel contract with OKG (Uniper), a major supplier of base load to the Nordic power supply system. Provided the plant is in operation and under the terms of the contract, Westinghouse will continue to provide reload fuel assemblies for the remaining Oskarshamn 3 unit until 2030. This contract continues the important relationship between OKG and Westinghouse’s Västerås Fuel Fabrication Facility in Västerås, Sweden.
“This contract is a confirmation of the extensive trust OKG has put in Westinghouse Sweden´s continued ability to deliver high-performance fuel assemblies. It also confirms our position as the leading BWR-fuel supplier in Northern Europe,” said Aziz Dag, Westinghouse vice president and managing director, Northern Europe.
Westinghouse will deliver its proven and reliable 10x10 SVEA96 Optima3 fuel. In 2018 Westinghouse will also introduce its next generation 11x11 BWR fuel design TRITON11TM , which has been carefully designed to provide superior fuel economy while maintaining the highest focus on a safe and reliable operation.
“The fuel fabrication facility in Västerås was established to deliver fuel to the Swedish nuclear fuel program. The first delivery was made to OKG’s first reactor Oskarshamn 1, and now, 50 years later, I am proud to say we are still supplying OKG and other customers around the world with the most modern fuel designs,” said Johan Lundberg, managing director, Swedish fuel operations.
To learn more about Westinghouse Electric Company, a Toshiba company, and our vision to be the first to innovate the next technology, practice or solution that helps our customers generate safer, cleaner, more reliable energy visit www.westinghousenuclear.com .
Westinghouse Electric Company
Desk: +1 412-374-4744
Cell: +1 724-272-2997
External Communications Manager
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skrive dig op her og du vil løbende modtage pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
ASTRAZENECA10.12.2017 23:47 | pressemeddelelse
AstraZeneca’s Calquence (acalabrutinib) Shows Potential in Chronic Lymphocytic Leukaemia Trials
NJ-CELGENE/BLUEBIRD-BIO10.12.2017 16:32 | pressemeddelelse
Celgene Corporation and bluebird bio Announce Updated Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti-BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASH Annual Meeting
GA-GILEAD-SCIENCES/KITE10.12.2017 16:32 | pressemeddelelse
Kite Announces Long-Term Data From Pivotal ZUMA-1 Study of Yescarta™ (Axicabtagene Ciloleucel) in Patients With Refractory Large B-cell Lymphoma
MA-TAKEDA/SEATTLE10.12.2017 14:02 | pressemeddelelse
Takeda and Seattle Genetics to Present Positive Data from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma
ASTRAZENECA9.12.2017 19:02 | pressemeddelelse
AstraZeneca’s Calquence (acalabrutinib) Demonstrates Activity in Relapsed or Refractory Mantle Cell Lymphoma Trial
JANSSEN9.12.2017 18:21 | pressemeddelelse
Sustained Benefit in Patients with Relapsed/Refractory Mantle Cell Lymphoma Demonstrated by 3.5 Year Follow-up Data of Imbruvica®▼(ibrutinib)
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum